Here, we selected a panel of low-passage BRAF-mutant melanoma cell lines that were established and maintained at 5% oxygen tension to mimic physiological oxygen concentrations and were sensitive to the MEK inhibitor selumetinib and the BRAF inhibitor vemurafenib. Here, BRAF is linked to melanoma.